Cargando…

Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice

AMD3100, also known as plerixafor, was originally developed as an anti-human immunodeficiency virus (HIV) drug, and later characterized as a C-X-C chemokine receptor type 4 (CXCR4) antagonist. Previous reviews have focused on the application of AMD3100 in the treatment of HIV, but a comprehensive ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Tao, Li, Xiaobo, You, Shuo, Bhuyan, Soumitra S., Dong, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947283/ https://www.ncbi.nlm.nih.gov/pubmed/27429863 http://dx.doi.org/10.1186/s40164-016-0050-5

Ejemplares similares

AMD3100/CXCR4 Inhibitor
por: De Clercq, Erik
Publicado: (2015)

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo
por: Yu, M, et al.
Publicado: (2011)

MOBILIZATION STUDIES IN COMPLEMENT-DEFICIENT MICE REVEAL THAT OPTIMAL AMD3100 MOBILIZATION OF HEMATOPOIETIC STEM CELLS DEPENDS ON COMPLEMENT CASCADE ACTIVATION BY AMD3100-STIMULATED GRANULOCYTES
por: Lee, HakMo, et al.
Publicado: (2009)

MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias
por: Spinello, I, et al.
Publicado: (2011)

CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011)

Combinatorial G-CSF/AMD3100 Treatment in Cardiac Repair after Myocardial Infarction
por: Rüder, Constantin, et al.
Publicado: (2014)

Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke
por: Walter, Helene L, et al.
Publicado: (2015)

VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
por: Meeson, Richard, et al.
Publicado: (2018)

Alpha-tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation combined injury in mice
por: Singh, Vijay K., et al.
Publicado: (2014)

AMD3100 inhibits the migration and differentiation of neural stem cells after spinal cord injury
por: Liu, Jia-Ming, et al.
Publicado: (2017)

Functional Phenotypes of Peritoneal Macrophages Upon AMD3100 Treatment During Colitis-Associated Tumorigenesis
por: Wu, Shuai, et al.
Publicado: (2022)

The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Wang, Shan, et al.
Publicado: (2020)

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation
por: Zhou, Jun, et al.
Publicado: (2020)

CXCR4 Antagonist AMD3100 Modulates Claudin Expression and Intestinal Barrier Function in Experimental Colitis
por: Xia, Xian-Ming, et al.
Publicado: (2011)

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
por: Kim, Ha-Yon, et al.
Publicado: (2010)

[(18)F]DPA-714 PET Imaging of AMD3100 Treatment in a Mouse Model of Stroke
por: Wang, Yu, et al.
Publicado: (2014)

AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem/progenitor cells
por: Im, Jin Young, et al.
Publicado: (2014)

Effect of Endogenous Bone Marrow Derived Stem Cells Induced by AMD-3100 on Expanded Ischemic Flap
por: Jeong, Hii-Sun, et al.
Publicado: (2014)

Administration of AMD3100 in endotoxemia is associated with pro-inflammatory, pro-oxidative, and pro-apoptotic effects in vivo
por: Seemann, Semjon, et al.
Publicado: (2016)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)

C-X-C-Chemokine-Receptor-Type-4 Inhibitor AMD3100 Attenuates Pulmonary Inflammation and Fibrosis in Silicotic Mice
por: Sun, Qixian, et al.
Publicado: (2022)

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
por: Broxmeyer, Hal E., et al.
Publicado: (2005)

Inhibition of CXCR4 in Spinal Cord and DRG with AMD3100 Attenuates Colon-Bladder Cross-Organ Sensitization
por: Zhang, Hengshuai, et al.
Publicado: (2022)

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model
por: Kang, Yubin, et al.
Publicado: (2010)

Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4
por: Aghanejad, Ayuob, et al.
Publicado: (2014)

CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats
por: Mason, Briana, et al.
Publicado: (2021)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
por: Maeda, Yosuke, et al.
Publicado: (2014)

Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS
por: Rabinovich-Nikitin, Inna, et al.
Publicado: (2016)

Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13
por: Li, Pengcui, et al.
Publicado: (2016)

Targeting CXCL12/CXCR4 Signaling with AMD3100 Might Selectively Suppress CXCR4+ T-Cell Chemotaxis Leading to the Alleviation of Chronic Prostatitis
por: Zhang, Meng, et al.
Publicado: (2022)

HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration, and invasion in lung cancer
por: Muralidharan, Ranganayaki, et al.
Publicado: (2015)

CXCR4 antagonist AMD3100 elicits analgesic effect and restores the GlyRα3 expression against neuropathic pain
por: Liu, Xiaoming, et al.
Publicado: (2017)

Comparison of the Response to the CXCR4 Antagonist AMD3100 during the Development of Retinal Organoids Derived from ES Cells and Zebrafish Retina
por: Wu, Yihui, et al.
Publicado: (2022)

AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome
por: McDermott, David H, et al.
Publicado: (2011)

The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
por: Berning, Philipp, et al.
Publicado: (2018)

Abstract 48: A Clinically Relevant Protocol for Vascularized Composite Allotransplantation Using A Single Dose of AMD3100 for Stem Cell Mobilization
por: Swearingen, Bruce J., et al.
Publicado: (2017)

CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
por: Ullah, Aftab, et al.
Publicado: (2019)

Is the U(3100) strange diquonium?
por: Siebert, Hans-Wolfgang
Publicado: (1987)

Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
por: Hollenberg, Rebecca K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f8bhbdbgnrn5v6bresg8df6gau